Vertex Pharmaceuticals (VRTX) Gross Profit (2009 - 2026)

Vertex Pharmaceuticals' Gross Profit history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Gross Profit rose 7.76% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $10.5 billion, a 10.35% increase from a year earlier, with the FY2025 full-year figure at $10.4 billion, up 9.07% from the prior year.
• Gross Profit fell to $2.6 billion in Q1 2026 per VRTX's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Gross Profit topped out at $2.7 billion in Q4 2025 and bottomed at $1.9 billion in Q1 2022.
• The 5-year median for Gross Profit is $2.3 billion (2024), against an average of $2.3 billion.
• Across the five-year window, Gross Profit climbed 23.57% in 2022 and gained 2.52% in 2025, its largest moves.
• Year by year, Gross Profit stood at $2.0 billion in 2022, then gained by 6.45% to $2.1 billion in 2023, then grew by 15.76% to $2.5 billion in 2024, then climbed by 9.46% to $2.7 billion in 2025, then declined by 4.77% to $2.6 billion in 2026.
• Per Business Quant, the three latest VRTX Gross Profit figures stand at $2.6 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025).